How would you describe your practice?

• Community: 
• Academic: 
• Private practice:

How many patients with hidradenitis suppurativa (HS) do you see per month?

Approximately what percentage (%) of your HS patients are moderate/severe (Hurley stage II–III)?

The number of diagnosed moderate to severe HS patients in the US is closest to:

• <300,000
• 300,000-400,000
• 400,000-500,000
• >500,000

What proportion (%) of your HS patients on biologics do you consider well-controlled?

What percentage (%) of your moderate/severe patients are currently receiving biologic therapy?

And what percentage (%) do you expect will be receiving biologic therapy in 5 years?

Of your patients currently receiving biologic therapy, what percentage (%) are on each product?

• Bimzelyx (Bimekizumab):
• Humira (Adalimumab):
• Cosentyx (Secukinumab):
• Other (specify):

In 5 years, what percentage (%) of your treated moderate-severe patients do you expect will be on each product?

• Bimzelyx (Bimekizumab):
• Humira (Adalimumab):
• Cosentyx (Secukinumab):
• Sonelokimab (IL-17 A/F nanobody):
• JAK inhibitor (povorcitinib or upadacitinib):
• Other (please specify):

What are your thoughts on sonelokimab (IL-17 A/F nanobody)? Please be specific.

MoonLake will report phase 3 data from the VELA trial of sonelokimab in moderate to severe HS in September. In each of the following scenarios, what will be your split between Cosentyx/Bimzelyx/sonelokimab use at steady state?

• Scenario A: Delta of 15%
  • Cosentyx
  • Bimzelyx
  • Sonelokimab
• Scenario B: Delta of 20%
  • Cosentyx
  • Bimzelyx
  • Sonelokimab
    
    
• Scenario C: Delta of 25%
  • Cosentyx
  • Bimzelyx
  • Sonelokimab

The prescribing label for Bimzelyx reports a HiSCR-75 delta of 17.5% from two phase 3 trials of bimekizumab. In your practice, do you observe the efficacy of Bimzelyx to be:

• Worse: 
• Similar: 
• Better:

Please elaborate on your answer to the previous question.

Which investigational treatment for HS in development are you most excited for? Select one.

• Other, (please specify)

Would you consider administering a biologic at an earlier stage (Hurley I) to prevent progression of the disease? Please elaborate.